41
Participants
Start Date
November 9, 2020
Primary Completion Date
April 29, 2024
Study Completion Date
April 29, 2024
Placebo
TAK-079 placebo-matching SC injection.
TAK-079
TAK-079 SC injection.
Azienda Policlinico Umberto I, Roma
Univerzitetni klinicni Center Ljubljana, Ljubljana
Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda, Sofia
University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD, Sofia
Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia, Sofia
University Multiprofile Hospital for Active Treatment Sofiamed OOD, Sofia
University Clinical Centre Maribor, Maribor
Medical Center OK!Clinic+LLC International Institute of Clinical Research, Kyiv
University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv
CNE Kyiv City Clinical Hospital #9 of Exec. Body of Kyiv City Council Kyiv City State Admin, Kyiv
University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski EAD, Pleven
Hospital de La Santa Creu i Sant Pau, Barcelona
Corporacio Sanitaria Parc Tauli, Sabadell
C.A.U de Burgos - Hospital Universitario de Burgos, Burgos
Klinicki bolnicki centar Zagreb, Zagreb
University Hospital Merkur, Zagreb
MNE Regional Clinical Hospital n a O F Herbachevskyi of Zhytomyr Regional Council, Zhytomyr
Onkologische Schwerpunktpraxis Kurfurstendamm, Berlin
A.O.U. Maggiore della Carita, Novara
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan
University of Virginia, Charlottesville
University General Hospital of Patras, Pátrai
Leo W. Jenkins Cancer Center, Greenville
Hospital Universitario Quironsalud Madrid, Madrid
Hospital General Universitario Gregorio Maranon, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario Principe de Asturias, Meco
Hospital Universitario Virgen del Rocio - PPDS, Málaga
Clinical Hospital Centre Osijek, Osijek
University of Florida, Gainesville
Hospital Universitario Central de Asturias, Oviedo
Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Trieste
OnkoNet Marburg GmbH, Marburg
Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna
Municipal Non-profit Enterprise Ternopil Regional Clinical Hospital of Ternopil Regional Council, Ternopil
Hospital Universitari i Politecnic La Fe de Valencia, Valencia
"Municipal Non-profit Enterprise City Clinical Hospital # 4 of Dnipro City Council - PPDS", Dnipro
Municipal Non-profit Enterprise Mykolayiv Regional Clinical Hospital the Mykolayiv Regional Council, Mykolaiv
Georgios Papanikolaou General Hospital of Thessaloniki, Thessaloniki
Universitatsklinikum Frankfurt, Frankfurt am Main
State Institution Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine, Lviv
Azienda Ospedaliera Universitaria Federico II, Napoli
Rotkreuzklinikum Munchen, München
Arizona Clinical Research Center - Hunt - PPDS, Tucson
Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi, Catania
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
Bleeding and Clotting Disorders Institute, Peoria
Massachusetts General Hospital, Boston
Boston Medical Center, Boston
General Hospital of Athens - George Gennimatas, Athens
Saiseikai Central Hospital, Minato-Ku
Nihon University Itabashi Hospital, tabashi City
Hospital del Mar, Barcelona
Lead Sponsor
Takeda
INDUSTRY